Cover Image
市場調查報告書

腮腺炎 : 開發平台分析

Mumps - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 271822
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
腮腺炎 : 開發平台分析 Mumps - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 44 Pages
簡介

腮腺炎是病毒性的接觸感染疾病,產生伴隨唾液腺疼痛的腫脹。病原病毒由個人間的對飛沫感染(鼻涕等),和沾有病毒的唾液之物直接接觸等方式擴大。主要的症狀為,發熱和臉的疼痛,頭痛,喉嚨的疼痛,太陽穴和下巴發腫,耳下腺的腫脹等。主要的治療方法有(緩和症狀)止痛藥等。

本報告提供全球各國的腮腺炎(流行性腮腺炎)治療用的開發中產品的開發情形相關分析、開發中產品的開發、上市的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

腮腺炎概要

治療藥的開發

  • 腮腺炎開發中產品:概要
  • 腮腺炎開發中產品:比較分析

各企業開發中的腮腺炎治療藥

大學/研究機關研究中的腮腺炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

腮腺炎治療藥:開發中的產品一覽(各企業)

腮腺炎治療藥:研究中的產品一覽(大學/研究機關)

腮腺炎治療藥開發企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • China National Pharmaceutical Group Corporation
  • GlaxoSmithKline Plc
  • Organic Vaccines
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

腮腺炎:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 各投藥法
  • 各分子類型

藥物簡介

  • 麻疹、腮腺炎、德國麻疹(MMR)細胞療法
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • MMR+水痘疫苗
  • MMR活病毒疫苗(新三種混合疫苗)
  • 麻疹strain schwarz 、腮腺炎strain RIT 4385、德國麻疹strain wistar RA 27/3疫苗
  • 腮腺炎疫苗

腮腺炎治療藥:開發中產品的最新趨勢

腮腺炎治療藥:開發暫停的產品

腮腺炎相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8243IDB

Summary

Global Markets Direct's, 'Mumps - Pipeline Review, H2 2016', provides an overview of the Mumps pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mumps, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mumps and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mumps
  • The report reviews pipeline therapeutics for Mumps by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Mumps therapeutics and enlists all their major and minor projects
  • The report assesses Mumps therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Mumps

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mumps
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mumps Overview
  • Therapeutics Development
    • Pipeline Products for Mumps - Overview
    • Pipeline Products for Mumps - Comparative Analysis
  • Mumps - Therapeutics under Development by Companies
  • Mumps - Therapeutics under Investigation by Universities/Institutes
  • Mumps - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Mumps - Products under Development by Companies
  • Mumps - Products under Investigation by Universities/Institutes
  • Mumps - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • China National Pharmaceutical Group Corporation
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline Plc
    • Prometheon Pharma, LLC
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Mumps - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (measles + mumps + rubella + varicella) (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles + mumps + rubella + varicella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mumps - Dormant Projects
  • Mumps - Product Development Milestones
    • Featured News & Press Releases
      • Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mumps, H2 2016
  • Number of Products under Development for Mumps - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Mumps - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Mumps - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016
  • Mumps - Pipeline by China National Pharmaceutical Group Corporation, H2 2016
  • Mumps - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Mumps - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Mumps - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Mumps - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Mumps - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Mumps - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Mumps, H2 2016
  • Number of Products under Development for Mumps - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top